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Biology of Chemotherapy-re lated Bone
Necros is and Therapeut ic Impl icat ions
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Overview: Osteonecrosis (ON) is a common complication
of chemotherapy and defined as death of all cellular ele-
ments of bone. It predominantly affects the femoral head
but can affect several other sites and occur multifocally.
Glucocorticoid seems to be the main etiology, although its
pathogenesis is ischemia. The mechanism of ischemia ini-
tiation is discussed. Intravascular coagulation obstructing
microcirculation has been proposed; raising intraosseous
pressure may cause inhibition of microcirculation. Direct
cytotoxicity on osteocytes has also been suggested as a
probable pathomechanism. The Association of Research on
Osseous Circulation (ARCO) has published a detailed clas-
sification which is the basis for differential therapy. ARCO
stage I seems to be best treated by core decompression,
which means drilling a canal from the bone cortex into the
necrotic lesion in order to release increased intraosseous
pressure. Bone grafting and proximal femur osteotomies
have proven to be valid therapies in stages II and III. ARCO
stage IV may best be treated by total surface hip replace-
ment or common total joint replacement. Because of the
typically young age of patients with ON, joint-preserving
techniques are preferred if possible.
OSTEONECROSIS (ON) is a common complication ofchemotherapy for different tumors. It predomi-
nantly occurs in the femoral head (FH), but it also occurs
in the proximal humerus, the knee, the ankle, and the
elbow, and is multifocal.13 ON is defined as, “…death of all
cellular elements of bone,”14 and can be of traumatic or
non-traumatic17 origin.
Epidemiology and Etiology
ON accounts for approximately 10% of the more than
500,000 total joint replacements performed annually in
the United States.17 ON patients are young in general,
and patients suffering from chemotherapy-related ON,
tend to be even younger. The average age of patients
receiving total hip replacement (THR) for femoral head
necrosis (FHN) is 38 with only 20% of patients being more
than 50 years old at the time of operation.20 In the
AIEOP-ALL-95 study of 1,421 patients younger than age
18 with acute lymphoblastic leukemia (ALL), 15 patients
(1.1%) were diagnosed with 29 symptomatic ON lesions.2
During the induction phase, 60 mg/sqm body surface
prednisone were given, and, during reinduction, 10 mg/
sqm dexamethasone. From diagnosis of ALL to ON evi-
dence, a mean 17 months (range 8 to 45 months) time
delay was found. Single cases of ON related to chemother-
apy not containing glucocorticoid are reported and related
to cyclophosphamide.12 Bilateral involvement of the FH is
ranging from 39.8% to 88.5%.19 Intravenous methylpred-
nisolone as pulse therapy over 3 months to treat acute
organ transplant rejection is associated with the incidence
of FHN, and cumulative doses over 2,000 mg of intrave-
nous methylprednisolone over 3 months were critical for
the incidence of FHN.22
In a study of 2,500 cases of FHN, 34.7% were steroid-
associated, 21.8% were alcohol-related, and 37.1% were
considered to be idiopathic.3 Further etiologies are dysba-
rism, also termed Caisson disease,14 sickle cell anemia,
Gaucher’s disease, and inflammatory bowel disease.20 In
recent years, ON of the jaws related to bisphosphonate
therapy has been reported.18
Histopathology of Steroid-induced ON
The histologic signs of ON in human bone have been
described and classified from human FH core biopsies8:
Type 1: disappearance of hematopoietic marrow, sepa-
ration of lipocytes by edema or hemorrhage, and presence
of foam cells.
Type 2: necrosis of fatty marrow, which is largely
changed to an eosinophilic reticular pattern, with oil cysts
and necrosis of hematopoietic marrow.
Type 3: complete medullary and trabecular necrosis.
Type 4: complete necrosis with dense medullary fibrosis
and new bone formation in apposition to dead trabeculae
– termed “living woven bone.”10
Hereby, trabecular necrosis is defined by empty osteo-
cyte lacunae or pyknotic nuclei of osteocytes in the bone
trabeculae.33 Adjacent to osteonecrotic lesions, organizing
thrombi have been found in intraosseous arterioles and fat
emboli in intraosseous veins.33 Intravascular aggrega-
tions of fibrin clots were found on the venous side in late
stage necrotic FHs.27 Furthermore, a decrease in the
number of vessels supplying the FH and an infarct of an
intraosseous artery have been observed postmortem in
steroid-treated renal transplant patients.26
Pathogenesis of Steroid-induced ON
Ischemia is the principal pathomechanism of ON. Local
and systemic activation of intravascular coagulation
based on a hypercoagulable state of plasma has been
suggested as a pathomechanism.14 Jones et al. demon-
strated systemic fat embolism after renal transplantation
and associated steroid treatment14 and experimental in-
fusion of lipiodol into the iliac artery could produce fat
embolism of bone microcirculation of the respective ex-
tremity. This study suggested that original fat globules
embolizing bone vessels break up into smaller fat particles
embolizing subchondral capillaries of the FH and other
locations. Free fatty acids damage the endothelial wall,
activating platelets and procoagulants,14 thereby causing
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retrograde thrombus formation on the arteriolar side
and also bleeding because of lack of clotting factors and
platelets on the venous side. Increased plasma fibrinogen
levels have been reported under steroid treatment, which
could have a systemic effect on coagulation.21 In a clinical
study, Glueck et al. found thrombophilia and hypofibrin-
olysis in 12 patients with ON secondary to glucocorticoid
treatment.11
Fat cell hypertrophy, which is another suggested patho-
mechanism of ON, was found in the femur of rabbits after
5-month methylprednisolone treatment.30 The growth of
fat cells in the intraosseous compartment was suggested
to increase intraosseous pressure resulting in sinusoidal
compression and, thereby, diminished perfusion of bone.
In addition, glucocorticoids may be lipogenetic as dexa-
methasone treatment of a puri-potential cell line from
mouse bone marrow resulted in differentiation of these
cells into fat cells.6 Core decompression, by which a
channel is drilled into the osteonecrotic lesion for decom-
pression, resulted in a gradual normalization of FH blood
flow after steroid treatment in rabbits.
Kenzora and Glimcher postulated that ON is initiated
by a direct cytotoxic effect of corticosteroids. A subchon-
dral fracture of an FHN lesion is caused by direct loading,
and the biologic repair processes consists of revasculariza-
tion and formation of new bone on the surface of the dead
bone trabeculae.10 Other works found fatty necrosis of
osteocytes in steroid-treated rabbits and suggested that
the changes of lipid metabolism under steroid treatment
could be a causative factor for osteocyte death as an initial
event.15 These studies reported no sign of impaired blood
supply to the FH.
Experimental Models of ON
A single intramuscular methylprednisolone injection
of 20 mg/kg to male adult Japanese white rabbits pro-
duced characteristic histologic signs of femoral and hu-
meral ON.33 A combination of the Shwartzman reaction
and corticosteroid injections produced femoral and hu-
meral osteonecrotic lesions in male, adult New Zealand
white rabbits.32 Rabbits were injected with the bacterial
endotoxin lipopolysaccharide intravenously twice at an
interval of 24 hours, followed by three injections of meth-
ylprednisolone 20 mg/kg at 24 hours intervals.
Classification of FHN
A classification of ON has been developed by the ARCO
based on the older classification by Ficat8 as outlined in
Table 1.20
The crescent sign represents separation of the subchon-
dral plate from the underlying necrotic cancellous bone
and becomes evident on magnetic resonance imaging
(MRI) and radiographs.
Therapeutic Implications
Treatment of ON related to chemotherapy/glucocorti-
coids is a challenge because of the young age of pa-
tients. In a study of ON following chemotherapy for
ALL, patient age was a mean of 18 (range 14 to 26
years).31 THR is not the preferred treatment in the young
patient because of increased risk of several revisions in
young age.20 The young age of patients with nontraumatic
FHN advocates joint-preserving operative techniques in-
cluding proximal femoral osteotomies,7 core decompres-
sion, and bone grafting.31
Core decompression has been shown to have a good
outcome when performed in the early stage of FHN, but
poor long-term results have been reported for core decom-
pression and nonvascularized bone grafting.23 Core de-
compression has been suggested for stage I and IIA FHN
but not in cases with evidence of cystic changes in the FH
on plain radiographs.4 None of 11 stage I hips treated with
either core decompression or vascularized fibular graft
needed THR.25 Among hips with stage I or III FHN, the
failure rate was significantly higher for hips treated with
core decompression than for hips treated with vascular-
KEY POINTS
● Osteonecrosis is a common complication of chemo-
therapy.
● Its pathogenesis is ischemia, and intravascular
coagulation, raised intraosseous pressure, or direct
cytotoxicity are the probable pathomechanisms.
● Modern osteonecrosis therapy is disease stage–
related, and it ranges from minor invasive core
decrompression to total joint replacement.
Table 1. ARCO Classification of FHN
Stage Characteristics
0 Bone-biopsy results consistent with avascular necrosis8 without
radiographic pathology
I Positive scintiscan or MRI, or both; lesions subdivided into medial,
central, or lateral depending on location of FH involvement; no
radiographic pathology
I-A 15% involvement of the FH
I-B 15 to 30% involvement of the FH
I-C 30% involvement of the FH
II Radiographic abnormalities (mottled appearance of the FH,
osteosclerosis, cyst formation, and osteopenia); no signs of collapse
of the FH on radiographs or CT scan; positive scintiscan and MRI;
no changes in acetabulum; lesions subdivided into medial, central,
or lateral depending on location of involvement of FH
II-A 15% involvement of the FH
II-B 15% to 30% involvement of the FH
II-C 30% involvement of the FH
III Crescent sign; lesions subdivided into medial, central, or lateral
depending on location of involvement of FH
III-A 15% crescent sign or 2 mm depression of FH
III-B 15% to 30% crescent sign, or 2 mm to 4 mm depression of FH
III-C 30% crescent sign, or 4 mm depression of FH
IV Articular surface flattened radiographically and joint space shows
narrowing; changes in acetabulum with evidence of osteosclerosis,
cyst formation, and marginal osteophytes
Abbreviations: ARCO, Association of Research on Osseous Circulation; CT,
computerized tomography; FH, femoral head; FHN, femoral head necrosis;
MRI, magnetic resonance imaging.
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ized fibular grafting.25 In a study of vascularized fibular
grafting, the 50-month survival rate was 89% in stage II
FHN and 81% in stage III hips.25 The same study found
50-month survival rates of 65% for stage II hips and of
21% of stage III hips after core decompression.
Intertrochanteric flexion osteotomy is a joint preserving
proximal femur osteotomy therapy for FHN.7 The princi-
ple of this procedure is to deflect the osteonecrotic lesion
away from the weight-bearing area by an intertrochan-
teric osteotomy. This method requires a relative long
phase of postoperative immobilization and high patient
compliance.
Mean age at operation of patients treated with intertro-
chanteric flexion osteotomy for FHN in the authors study7
was 38 (range 13 to 62 years). The Harris hip score, a
commonly used semi-quantitative score of hip function
and related quality of life, was improved by flexion osteot-
omy independent from ON stage. Joint mobility was lower
after flexion osteotomy for all the hips and unchanged for
stage II hips. This and the poor return to work may be a
drawback of the method. Pain, a major indication for
operation, was improved by flexion osteotomy. Pain and
walking ability were reported to be improved in another
study of flexion osteotomy.9 In a study on corrective
proximal femoral osteotomy, a good to excellent outcome
with an increase in Harris hip score has been described.20
The rate of early postoperative complications was 9% in
our study, compared to 17% in a study by Schneider et
al.24 Bony nonunion and pseudarthrosis are method-
specific complications. The rate of failure of flexion osteot-
omy in our material7 was 10% after 5 years and 27%
during the whole follow-up period, although other groups
reported 27% after 5 years24 and 24% after 11.5 years.20
Alcohol abuse by the patient contributed to the higher rate
of failure of flexion osteotomy. We found an overall sur-
vival (OS) rate of 90% in our study over 5 years. The
survival rate of stage II hips was 92%, and the survival
rate of stage III and IV hips was 88%. Schneider et al.
reported a 5-year survival probability of 70%, and 50%
after 10 years for flexion osteotomy.24
The necrotic angle is of prognostic value and is mea-
sured by adding the necrotic angle in the anteroposterior
and axial projection on the X-rays.16 In our study, the
failure rate for necrotic angles more than 200 degrees was
higher than for those hips with a necrotic angle less than
200 degrees. Also, Wagner et al. found that the outcome
for FHN with a necrotic angle more than 200 degrees
declined and that the outcome for those with a necrotic
angle of greater than 250 degrees was unsatisfying.29 A
survival probability of 90% was reported for flexion osteot-
omy when the necrotic angle was less than 180 degrees.24
Considering alternative proximal femur osteotomies,
Saito et al. suggested that intertrochanteric varus osteot-
omies are a good therapy for selected indications with
relatively small and shallow areas of necrosis where the
lateral head is intact. Complication rates of 55% and a
5-year failure rate of 72% have been presented for Sugio-
ka’s rotational osteotomy.
In the end stage of ON, collapse of the FH results in
secondary arthritis of the hip. At this stage, joint replace-
ment is indicated. The alternative to traditional THR for
selected patients is total surface hip replacement, a
method by which bone stock is spared and only the FH
surface is resected and covered by a metal surface.1 The
long-term results of THR are known to be worse than
those in matched groups of patients who have other
diseases than FHN involving the hip.28 The highest revi-
sion rates of THR are found in steroid-induced FHN and
FHN with underlying bone diseases such as sickle cell
disease5 (59% over a cumulative 5.5-year period).
Conclusion
Stage I ON may be treated by the little invasive core
decompression to release intraosseous pressure. Intertro-
chanteric flexion osteotomy is a safe and effective proce-
dure preferably in ARCO stage II but also in stage III
FHN and with a necrotic angle of less than 200 degrees. In
FHN associated with alcoholism, intertrochanteric flexion
osteotomy seems to have a higher failure rate. Hips with
Ficat stage IV FHN, rather, seem to benefit from total
surface hip replacement.
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